Filing Details
- Accession Number:
- 0001127602-10-006150
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-02-24 12:00:00
- Reporting Period:
- 2010-02-22
- Filing Date:
- 2010-02-24
- Accepted Time:
- 2010-02-24 18:01:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1097264 | Allos Therapeutics Inc | ALTH | Pharmaceutical Preparations (2834) | 541655029 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1202769 | L Paul Berns | 11080 Circlepoint Road Suite 200 Westminster CO 80020 | Chief Executive Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-02-22 | 100,000 | $0.00 | 234,167 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2010-02-23 | 4,304 | $7.51 | 229,863 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2010-02-24 | 7,362 | $7.57 | 222,501 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | Acquisiton | 2010-02-22 | 170,000 | $7.56 | 170,000 | $7.56 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 170,000 | 2011-02-22 | 2020-02-22 | No | 4 | A | Direct |
Footnotes
- Represents shares of common stock subject to restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs vest in a series of four (4) successive equal annual installments over the four (4)-year period measured from the Vesting Commencement Date, subject to Participant's Continuous Service through each such date.
- The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan under which Mr. Berns sold a portion of his holdings for tax and estate planning purposes.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $7.49 to $7.53. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $7.53 to $7.63. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
- Stock options vest according to the following schedule: Twelve forty-eighths of the total number of shares subject to this option shall vest twelve (12) months after the vesting commencement date and an additional one forty-eighths (1/48) of the total number of shares subject to the option become exercisable each one-month period thereafter, until all such shares are exercisable.
Billionaire Hedge Funds
